Montse Llinas-Brunet

This inventor holds 35 USPTO granted patents and 6 published patent applications, plus 1 CIPO patent and 7 EPO patents, primarily in Viral Inhibitors. Top assignees: Boehringer Ingelheim International Gmbh, Boehringer Ingelheim (Canada) Ltd., Boehringer Ingelheim Pharmaceuticals, Inc.. Active years: 2000-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Montse Llinas-Brunet. Retrieved from https://idiyas.com/inventor/montse-llinas-brunet

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 35 (Patent Applications = 6)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 7 (Patent Applications = 4)

Average Co-Inventor Count = 5.3

ph-index = 18

Forward Citations = 1,297(Granted Patents)

Location History:

Pierrefonds, CA (2000 - 2001)
D.D.O, CA (2002)
D.D.O., CA (2001 - 2004)
Dollards des Ormeaux, CA (2010)
Laval, CA (2003 - 2011)
Dollard-des-Ormeaux, CA (2000 - 2014)

Company Filing History:

17 out of 1,564

Boehringer Ingelheim International Gmbh

patents

14 out of 62

Boehringer Ingelheim (Canada) Ltd.

patents

4 out of 278

Boehringer Ingelheim Pharmaceuticals, Inc.

patents

Years Active: 2000-2014

Loading Chart...

Areas of Expertise:

Viral Polymerase Inhibitors

Hepatitis C Inhibitors

Macrocyclic Peptides

Tri-Peptides

Dipeptide Analogs

Peptide Analogues

Src Family SH2 Domain

Phosphotyrosine Mimics

35 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8912182 - Viral polymerase inhibitors (2014-12-16),

2. 8541402 - Viral polymerase inhibitors (2013-09-24),

3. 8476257 - Viral polymerase inhibitors (2013-07-02),

4. 8067438 - Hepatitis C inhibitor compounds (2011-11-29),

5. 7939667 - Hepatitis C inhibitor compounds (2011-05-10),

6. RE42164 - Hepatitis C inhibitor tri-peptides (2011-02-21),

7. RE41894 - Hepatitis C inhibitor tri-peptides (2010-10-25),

8. 7767818 - Hepatitis C inhibitor dipeptide analogs (2010-08-03),

9. 7749961 - Macrocyclic peptides active against the hepatitis C virus (2010-07-06),

10. RE41356 - Hepatitis C inhibitor tri-peptides (2010-05-24),

11. 7705146 - Hepatitis C inhibitor peptide analogs (2010-04-27),

12. 7696242 - Hepatitis C inhibitor peptide analogs (2010-04-13),

13. 7642235 - Macrocyclic peptides active against the hepatitis C virus (2010-01-05),

14. 7585845 - Hepatitis C inhibitor compounds (2009-09-08),

15. 7511157 - Hepatitis C inhibitor dipeptide analogs (2009-03-31),

Title: Innovator Profile: Montse Llinas-Brunet

Introduction: Montse Llinas-Brunet is a notable inventor based in Dollard-des-Ormeaux, Canada. With an impressive portfolio of 35 patents, Llinas-Brunet has made significant contributions to the field of virology, particularly concerning hepatitis C virus inhibitors.

Latest Patents: Among his latest patents are two innovative formulations, both titled "Viral Polymerase Inhibitors - Compounds of Formula I." These inventions are specifically designed to inhibit the hepatitis C virus's NS5B polymerase, providing potential avenues for effective treatments against the virus.

Career Highlights: Montse Llinas-Brunet has built a distinguished career, having worked with prominent organizations such as Boehringer Ingelheim International GmbH and Boehringer Ingelheim (Canada) Ltd. His work in these companies has played a crucial role in advancing antiviral research and development.

Collaborations: Throughout his career, Llinas-Brunet has collaborated with esteemed colleagues including Murray D. Bailey and Jean Rancourt. These partnerships reflect a commitment to innovation and the collective effort necessary for impactful research.

Conclusion: Montse Llinas-Brunet stands out as a prominent figure in the realm of pharmaceutical innovation. With his extensive patent portfolio and collaborations with leading companies and researchers, he continues to pave the way for new treatments against viral infections, showcasing the vital role of inventors in advancing healthcare solutions.

Profile summary based on public USPTO records.